US equities |
GOOGL $283.82 ▼-12.64% GOOG $282.32 ▼-12.29% MU $934.27 ▼-4.98% MSFT $530.14 ▼-0.16% AMZN $243.79 ▼-4.25% META $624.52 ▲+1.96% NVDA $213.66 ▼-0.80% AAPL $348.91 ▲+1.48%
FinancialContent

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

6.670 +0.040 (+0.60%)
Delayed Quote Updated: 4:00 PM EDT, Oct 29, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
Myriad Genetics to Participate in Goldman Sachs Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights Latest Oncology Portfolio Advancements and New Data at ASCO 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Adam Brufsky, MD, PhD, FACP Named Oncology Scientific Advisor to Myriad Genetics
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Where Myriad Genetics Stands With Analysts ↗
 
Via Benzinga
News headline image
Where Myriad Genetics Stands With Analysts ↗
 
Via Benzinga
News headline image
Earnings Preview For Myriad Genetics ↗
 
Via Benzinga
News headline image
Myriad Genetics Adds Folate Receptor Alpha to Precise™ Oncology Solutions Portfolio to Expand Treatment Options for Women Living with Ovarian Cancer
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Why CohBar Shares Are Trading Lower By 161%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For May 23, 2023 ↗
 
Via Benzinga
News headline image
Lilium, Myriad Genetics And Other Big Stocks Moving Higher In Tuesday's Pre-Market Session ↗
U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. 
Via Benzinga
News headline image
Exact Sciences Serves Investors Exactly What They Wished For
Diagnostic and cancer test products provider Exact Sciences Corp. (NASDAQ: EXAS) saw its shares spike over 17% on its Q1 2023 earnings results. The 
Via MarketBeat
News headline image
Myriad Genetics Earns 2023 Great Place to Work Certification™
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports First Quarter 2023 Financial Results; Achieves 10% Revenue Growth Year-Over-Year, the Second Consecutive Quarter of Double-Digit Year-Over-Year Revenue Growth; Raises Mid-Point of 2023 Revenue Guidance Range
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Why Atlassian Shares Are Trading Lower By 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session ↗
Gainers 
Via Benzinga
News headline image
Myriad Genetics to Participate in BofA Securities Healthcare Conference
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release First Quarter Financial Results on May 3, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
77% of Americans have used addictive behaviors or unhealthy coping mechanisms to manage their mental health, according to Myriad Genetics nationwide survey
Medication failure leads 45% of respondents with depression and/or anxiety to turn to unhealthy coping mechanisms 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Intermountain Precision Genomics and Myriad Genetics Now Offer Solid Tumor Testing in All 50 States
About Intermountain Health Headquartered in Utah with locations in seven states and additional operations across the western U.S., www.intermountainhealth.org is a nonprofit system of 33 hospitals, 385... 
Via PRUnderground
News headline image
Myriad Genetics and Intermountain Precision Genomics Now Offer Solid Tumor Testing in All 50 States with Latest NY State Certification
Intermountain Precision Genomics Laboratory receives certification from NYS Department of Health Clinical Laboratory Evaluation Program 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics and SimonMed® Imaging Collaborate to Advance Precision Medicine with New Genetic Risk Assessment Program
New program will increase access to affordable genetic testing while also helping to identify and elevate high-risk patient care 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
The 3 Best CRISPR Stocks to Buy Now Before They Skyrocket ↗
Moving forward, CRISPR could revolutionize the way we treat thousands of diseases. The best CRISPR stocks will profit from it. 
Via InvestorPlace
News headline image
Illumina and Myriad Genetics expand partnership to broaden access to HRD testing in the United States
Strategic partnership offers a unique combination of diagnostic development and commercialization capabilities to the pharmaceutical industry 
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday ↗
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
News headline image
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
News headline image
Myriad Genetics Applauds New Expanded Carrier Screening Practice Guidelines from NSGC
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight® Volumes
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Release Fourth-Quarter Financial Results on Feb. 28, 2023
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics to Participate in Upcoming Healthcare Conferences
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
Myriad Genetics Highlights 2022 Research Findings that Help Advance More Accessible and Equitable Genetic Testing
From Myriad Genetics, Inc.
Via GlobeNewswire
News headline image
3 Small Caps That Have Big Upside
If market sentiment stays bullish, small caps with depressed shares prices and valuation could turn into big-time outperformers. 
Via MarketBeat
Topics Economy
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >